Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience

Affiliations

• ¹ Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza, Turin, Italy.
• ² Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy; Pediatric Oncohematology, Stem Cell Transplantation and Cell Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
• ³ Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy.
• ⁴ Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy.
• ⁵ Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Italy; Division of Hematology, Allogeneic Transplant and Cell Therapy Unit, AOU "Città della Salute e della Scienza di Torino" University of Turin, Italy.
• ⁶ Division of Hematology, Allogeneic Transplant and Cell Therapy Unit, AOU "Città della Salute e della Scienza di Torino" University of Turin, Italy.
• ⁷ Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza, Turin, Italy. Electronic address: cerranomarco@gmail.com.